Skip to main content

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Mecanismos de neuromodulación en la hipertensión portal: nuevas posibilidades terapéuticas en la cirrosis hepática

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 69575
Reference: PI13/01289
Duration: 01/01/2014 - 30/06/2017

Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary clinical and experimental approach

IP: -
Collaborators: Ignacio Ferreira González, José Antonio Barrabés Riu, Bustamante Rangel, Alejandro, Joan Montaner Villalonga, Immaculada Raurell Saborit, Joan López Hellin, Antonio González Fernández, Antonia Sambola Ayala, Marta García Ramírez, Joaquin Lopez Soriano, Anna Meseguer Navarro, Antonio Rodríguez Sinovas, Artur Evangelista Masip, Rafael Simó Canonge, Santiago Aguade Bruix, Francesc Moreso Mateos, Cristina Hernández Pascual, Anna Penalba Morenilla, Maria Nieves Martell Pérez-Alcalde, Neus Bellera Gotarda, Natalia Ramos Terrades, Andreea Ciudin Mihai, Maria Mar Hernandez Guillamon, Yolanda Riba Llena, Meritxell Ibernon Vilaró, Ignasi Barba Vert, Jordi Bañeras Rius, Bruno García del Blanco, Daniel Serón Micas, María Eugenia Espinel Garuz, Marisol Ruiz Meana, Maria Pilar Delgado Martínez, Irene Montllor Ramoneda, Irina Betsabe Torres Rodriguez, Javier Inserte Igual, Anna Rosell Novel, Olga Simó Servat, Joan Genescà Ferrer, Mònica Pons Delgado, M Antonieta Azancot Rivero, Maria Nazarena Pizzi, M Antonieta Azancot Rivero
Funding agency: Instituto de Salud Carlos III
Funding: 825000
Reference: PIE13/00027
Duration: 01/01/2014 - 30/06/2018

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Berta Saez Gimenez

Berta Saez Gimenez

Main researcher
Pneumology
Read more
Hector Rios Duro

Hector Rios Duro

Research technician
Kidney Physiopathology
Read more
Ruben Fernández Galera

Ruben Fernández Galera

Postdoctoral researcher
Cardiovascular Diseases
Read more
Alba Estela García Fernández

Alba Estela García Fernández

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.